Years back ACR said they are aiming for double digit returns on...

  1. 6,589 Posts.
    lightbulb Created with Sketch. 53
    Years back ACR said they are aiming for double digit returns on each generic. So if a generic is costing some $3.000,000 to $3,500,000 from development to market, and if double digit returns are (hopefully ) around 15%, we are potentially looking only at $450,000 to $525,000 returns (that have to be shared with our partners?) . So it will only be volume ANDA approvals and launches that will make any serious money. The up side is winning generics can last decades. The downside is, does ACR have the know how to pick winning ANDA formulas? I not sure that they do. Jet
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
1.9¢
Change
0.000(0.00%)
Mkt cap ! $7.747M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
6 677000 1.9¢
 

Sellers (Offers)

Price($) Vol. No.
2.0¢ 646239 2
View Market Depth
Last trade - 10.56am 19/06/2025 (20 minute delay) ?
ACR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.